New

Welcome. Sign in or register.

Refer A Friend | Contact Us

Providing investors with the
tools to make informed decisions.

Providing investors with the
tools to make informed decisions.

Tracking 1053 U.S. listed China Stocks and Counting...

Tracking 1535 U.S. Stocks and Counting...

GeoResearch GeoBargains GeoSpecials Guidance Make Goods Penny Stocks Recent Additions All Companies

Kun Run Biotech (PINK:KURU)

GeoProfile
Overview
GeoResearch
Message Board
Alerts Log
GeoWire Log
Third party data
Quote
Level II
Historical Prices
Options
Profile
Financials
Charts
News
Filings
Insiders

Do you represent this company?

Learn how we can help increase your exposure to investors.

All Research Comments & Business Outlook Deal Flow Financial Target Agreements Financials Investor Alert

Tuesday, April 27, 2010

2010 Performance targets:

$9,000,000, in the event the Company obtains PRC State Food and Drug Authority (“PRC SFDA”) approval for Entecavir on or prior to September 30, 2010; or
$7,150,000, in the event the Company does not obtain PRC SFDA approval for Entecavir on or prior to September 30, 2010.

KURU reported 2009 net income of $6,493,759.

Home | Market Activity | Research | Message Boards | My Account | Refer a Friend | Contact Us

About | Site Map | Privacy Policy | Terms of Service | Twitter | © 2009 GeoInvesting LLC

Articles | Asian Stock | Asian Stock Market | Asian Stocks | Business Outlook | Company Analysis | Company Profile
Day Trading | Stock Analysis| Stock Research

Statements and scenarios on GeoInvesting are not intended to be investment advice, but are based on some
commonly used investment guidelines. They are provided to aid investors in making their own investment decisions.
Please review GeoInvesting's complete disclosures and disclaimers under the link above regarding "Terms of Service."